PPARG2 Pro12Ala and ADAMTS9 rs4607103 as "insulin resistance loci" and "insulin secretion loci" in Italian individuals. the GENFIEV study and the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 4

Acta Diabetologica

Volumn 50, Issue 3, 2013, Pages 401-408

  Trombetta, M ^a,b   Bonetti, S ^a   Boselli, M L ^a   Miccoli, R ^c   Trabetti, E ^d   Malerba, G ^d   Pignatti, P F ^d   Bonora, E ^a,b   Del Prato, S ^c   Bonadonna, R C ^a,b  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

Author keywords

ADAMTS9; Insulin resistance; PPARG; Type 2 diabetes

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN;

ADAMTS9 GENE; ADULT; ARTICLE; CONTROLLED STUDY; DIABETOGENESIS; ETHNIC GROUP; FEMALE; GENE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; ITALIAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET CELL FUNCTION; PHENOTYPIC VARIATION; PPARG2 GENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADAM PROTEINS; ADULT; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INSULIN; INSULIN RESISTANCE; ITALY; MALE; MIDDLE AGED; PHENOTYPE; POINT MUTATION; PPAR GAMMA; RISK FACTORS;

EID: 84879203883     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-012-0443-9     Document Type: Article

References (37)

1. Trombetta M, Calì A, Vettore M, Caruso B, Dorizzi R, Avogaro A, Bonora E, Bonadonna RC (2011) Type 2 diabetes mellitus: a disease of the governance of the glucose-insulin system. An experimental metabolic control analysis study. Nutrition, metabolism and cardiovascular disease in press
2. Ahlqvist E, Ahluwalia TS, Groop L (2011) Genetics of type 2 diabetes. Clin Chem 57:241-254
3. Scott RA, Lagou V, Welch RP et al (2012) Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet 44:991-1005
4. Morris AP, Voight BF, Teslovich TM et al (2012) Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 44:981-990
5. Florez JC (2008) Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: where are the insulin resistance genes? Diabetologia 51:1100-1110
6. Altshuler D, Hirschhorn JN, Klannemark M et al (2000) The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76-80
7. Lu M, Sarruf DA, Talukdar S et al (2011) Brain PPAR-gamma promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones. Nat Med 17:618-622
8. Ahmed W, Ziouzenkova O, Brown J et al (2007) PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? J Intern Med 262:184-198
9. Ludovico O, Pellegrini F, Di Paola R et al (2007) Heterogeneous effect of peroxisome proliferator-activated receptor gamma2 Ala12 variant on type 2 diabetes risk. Obesity (Silver Spring) 15:1076-1081
10. Buzzetti R, Petrone A, Ribaudo MC et al (2004) The common PPAR-gamma2 Pro12Ala variant is associated with greater insulin sensitivity. Eur J Hum Genet 12:1050-1054
11. Tonjes A, Scholz M, Loeffler M, Stumvoll M (2006) Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with Pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 29:2489-2497
12. Vanttinen M, Nuutila P, Pihlajamaki J et al (2005) The effect of the Ala12 allele of the peroxisome proliferator-activated receptor-gamma2 gene on skeletal muscle glucose uptake depends on obesity: a positron emission tomography study. J Clin Endocrinol Metab 90:4249-4254
13. Honka MJ, Vanttinen M, Iozzo P et al (2009) The Pro12Ala polymorphism of the PPARgamma2 gene is associated with hepatic glucose uptake during hyperinsulinemia in subjects with type 2 diabetes mellitus. Metabolism 58:541-546
14. Vaccaro O, Mancini FP, Ruffa G et al (2002) Fasting plasma free fatty acid concentrations and Pro12Ala polymorphism of the peroxisome proliferator-activated receptor (PPAR) gamma2 gene in healthy individuals. Clin Endocrinol (Oxf) 57:481-486
15. Zeggini E, Scott LJ, Saxena R et al (2008) Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 40:638-645
16. Boesgaard TW, Gjesing AP, Grarup N et al (2009) Variant near ADAMTS9 known to associate with type 2 diabetes is related to insulin resistance in offspring of type 2 diabetes patients-EUGENE2 study. PLoS ONE 4:e7236
17. Simonis-Bik AM, Nijpels G, van Haeften TW et al (2010) Gene variants in the novel type 2 diabetes loci CDC123/CAMK1D, THADA, ADAMTS9, BCL11A, and MTNR1B affect different aspects of pancreatic beta-cell function. Diabetes 59:293-301
18. Staiger H, Machicao F, Kantartzis K et al (2008) Novel meta-analysis-derived type 2 diabetes risk loci do not determine prediabetic phenotypes. PLoS ONE 3:e3019
19. Sanghera DK, Been L, Ortega L et al (2009) Testing the association of novel meta-analysis-derived diabetes risk genes with type II diabetes and related metabolic traits in Asian Indian Sikhs. J Hum Genet 54:162-168
20. Grarup N, Andersen G, Krarup NT et al (2008) Association testing of novel type 2 diabetes risk alleles in the JAZF1, CDC123/CAMK1D, TSPAN8, THADA, ADAMTS9, and NOTCH2 loci with insulin release, insulin sensitivity, and obesity in a population-based sample of 4,516 glucose-tolerant middle-aged Danes. Diabetes 57:2534-2540
21. Mancini FP, Vaccaro O, Sabatino L et al (1999) Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma2 is not associated with type 2 diabetes. Diabetes 48:1466-1468
22. Vangipurapu J, Stancakova A, Pihlajamaki J et al (2011) Association of indices of liver and adipocyte insulin resistance with 19 confirmed susceptibility loci for type 2 diabetes in 6,733 non-diabetic Finnish men. Diabetologia 54:563-571
23. Bonadonna RC (2004) Alterations of glucose metabolism in type 2 diabetes mellitus An overview. Rev Endocr Metab Disord 5:89-97
24. Bianchi C, Miccoli R, Bonadonna RC et al. (2010) Metabolic syndrome in subjects at high risk for type 2 diabetes: The genetic, physiopathology and evolution of type 2 diabetes (GENFIEV) study. Nutr Metab Cardiovasc Dis 21(9):699-705
25. Bonetti S, Trombetta M, Malerba G et al (2011) Variants and haplotypes of TCF7L2 are associated with beta-cell function in patients with newly diagnosed type 2 diabetes: the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 1. J Clin Endocrinol Metab 96:E389-E393
26. Bonetti S, Trombetta M, Boselli ML et al (2011) Variants of GCKR Affect Both {beta}-cell and kidney function in patients with Newly Diagnosed Type 2 Diabetes: the Verona Newly Diagnosed Type 2 Diabetes Study 2. Diabetes Care 34:1205-1210
27. Bonadonna RC, Heise T, Arbet-Engels C et al (2010) Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J Clin Endocrinol Metab 95:5028-5036
28. Lin CH, Yeakley JM, McDaniel TK, Shen R (2009) Medium- to high-throughput SNP genotyping using veracode microbeads. Methods Mol Biol 496:129-142
29. Florez JC, Jablonski KA, Sun MW et al (2007) Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab 92:1502-1509
30. Kanat M, Norton L, Winnier D, Jenkinson C, DeFronzo RA, Abdul-Ghani MA (2011) Impaired early - but not late-phase insulin secretion in subjects with impaired fasting glucose. Acta Diabetol 48:209-217
31. Gallwitz B, Kazda C, Kraus P, Nicolay C, Schernthaner G (2011) Contribution of insulin deficiency and insulin resistance to the development of type 2 diabetes: nature of early stage diabetes. Acta Diabetol. doi: 1007/s00592-011-0319-4
32. Schleinitz D, Tonjes A, Bottcher Y et al (2010) Lack of significant effects of the type 2 diabetes susceptibility loci JAZF1, CDC123/CAMK1D, NOTCH2, ADAMTS9, THADA, and TSPAN8/LGR5 on diabetes and quantitative metabolic traits. Horm Metab Res 42:14-22
33. Ylonen SK, Salminen I, Lyssenko V et al (2008) The Pro12Ala polymorphism of the PPAR-gamma2 gene affects associations of fish intake and marine n-3 fatty acids with glucose metabolism. Eur J Clin Nutr 62:1432-1439
34. Barrett EJ, Eggleston EM, Inyard AC et al (2009) The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. Diabetologia 52:752-764
35. Zhou Y, Zhang E, Berggreen C et al (2012) Survival of pancreatic beta cells is partly controlled by a TCF7L2-p53-p53INP1-dependent pathway. Hum Mol Genet 21:196-207
36. Bonora E, Targher G, Formentini G et al (2004) The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data from the verona diabetes complications study. Diabet Med 21:52-58
37. Bonora E, Capaldo B, Perin PC et al (2008) Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database. Nutr Metab Cardiovasc Dis 18:624-631